Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent apowerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

2002: In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion’s belt.

2003: In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms.

2004: On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.

2007: In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Isis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.

2009: In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus.

2011: Alnylam has now exceeded its goals from the first two such plans, growing its market cap from $416 million at the start of 2011 to over $13 billion today. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production.

2012: In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia.

2013: In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.

2014: In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million.

2015: In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.

2016: In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.

2020: In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. It employs more than 1,500 employees, the vast majority of which are in Massachusetts, and while the company is not yet profitable, it ended 2020 with product revenue of $306 million.

2021: On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Top-Ranked company for 2021: Collegium Pharmaceuticals

Build a top-tier, global, independent biopharmaceutical company founded on RNAi.

Harnessing a revolution in biology for human health(R).